Abstract
Biologics represent some of the most effective treatment options for moderate-severe psoriasis. However, insurance approvals and need for prior authorizations continue to cause barriers for many patients. We sought to determine whether race/ethnicity, insurance type, and provider specialty (ie, dermatology or rheumatology) affects biologic approval times. Records from the University of Miami were reviewed. 67 patients were included. The need for prior authorization was significantly associated with longer waits (7 days) and 38% of Caucasians experienced a long wait.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
